SGLT2抑制劑於心衰竭病人之應用

10.6666/ClinMed.202110_88(4).0107

陳筱郁；郭錦松

第2型鈉－葡萄糖共同運輸蛋白2抑制劑（SGLT2 inhibitor） ； 心衰竭住院（hospitalization for heart failure） ； 心因性死亡（cardiovascular death） ； 腎臟不良事件（renal outcomes） ； 堪薩斯市心肌病變問卷（Kansas City Cardiomyopathy Questionnaire）

臨床醫學月刊

88卷4期（2021 / 10 / 29）

645 - 648

繁體中文

第2型鈉－葡萄糖共同運輸蛋白（sodium glucose cotransporter 2, SGLT2）抑制劑如dapagliflozin以及empagliflozin等，在很多大型試驗中表現出可減少糖尿病病患或非糖尿病病患心衰竭住院發生率、心因性死亡發生率、腎臟不良事件發生率，以及可以改善心衰竭的堪薩斯市心肌病變問卷症狀分數。此類糖尿病藥物因為它的心血管益處，目前被建議使用在心衰竭的病患。

1. Aftab, Saba,Suresh, Rishwanth Vetrivel,Sherali, Nazleen(2020).Sodium-Glucose Cotransporter-2(SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease.Cureus,12,e10783.
2. Fitchett, D,Inzucchi, SE,Cannon, CP(2019).Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial.Circulation,139,1384-1389.
3. Joshi, Shruti S,Singh, Trisha,Newby, David E(2021).Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.Heart,107,1032-1038.
4. Lopaschuk, Gary D.,Verma, Subodh(2020).Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2(SGLT2) Inhibitors: A State-of-the-Art Review.JACC: Basic to Translational Science,5,632-644.
5. Maddox, Thomas M,Januzzi, James L, Jr,Allen, Larry A(2021).2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.J Am Coll Cardiol,77,772-810.
6. Maejima, Yasuhiro(2020).SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function.Front Cardiovasc Med,6,186.
7. McMurray, JJV,Solomon, SD,Inzucchi, SE(2019).Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.N Engl J Med,381,1995-2008.
8. Nakagawa, Yasuaki,Kuwahara, Koichiro(2020).Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.J Cardiol,76,123-131.
9. Nightingale, Brandon(2021).A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure.Cardiol Res,12,60-66.
10. Packer, M,Anker, SD,Butler, J(2020).Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.N Engl J Med,383,1413-1424.
11. Packer, Milton(2020).Moleclar, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure.J Am Heart Assoc,9,e016270.
12. Williams, David M.,Evans, Marc(2020).Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR Reduced Trials.Diabetes Ther,1925-1934.
13. Williams, David M.,Evans, Marc(2020).Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?.Diabetes Ther,2207-2219.
14. Zeng, Qingchun,Zhou, Qing,Liu, Weitao(2021).Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.Front Cardiovasc Med,8,636152.